
Johnson Pharmacare (JOHNPHARMA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-534.0K
Net Income
-534.0K
EPS (Diluted)
₹0.00
Balance Sheet Metrics
Total Assets
579.3M
Total Liabilities
17.6M
Shareholders Equity
561.7M
Debt to Equity
0.03
Cash Flow Metrics
Revenue & Profitability Trend
Johnson Pharmacare Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 25.3M | 32.6M | 7.6M |
Cost of Goods Sold | 90.0K | 0 | 20.9M | 27.9M | 6.7M |
Gross Profit | -90.0K | 0 | 4.3M | 4.8M | 860.0K |
Gross Margin % | 0.0% | 0.0% | 17.1% | 14.6% | 11.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 18.0K | 121.0K | 156.0K | 10.0K |
Other Operating Expenses | 698.0K | 1.9M | 1.9M | 2.9M | 834.1K |
Total Operating Expenses | 698.0K | 1.9M | 2.1M | 3.1M | 844.1K |
Operating Income | -788.0K | -2.0M | 2.2M | 1.3M | 15.9K |
Operating Margin % | 0.0% | 0.0% | 8.8% | 4.1% | 0.2% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -5.8M | -2.0M | -13.3M | 1.3M | 15.9K |
Income Tax | 0 | 0 | -379.0K | 377.0K | 4.1K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 28.1% | 26.0% |
Net Income | -5.8M | -2.0M | -12.9M | 967.0K | 11.7K |
Net Margin % | 0.0% | 0.0% | -51.1% | 3.0% | 0.2% |
Key Metrics | |||||
EBITDA | -4.1M | -2.0M | 2.2M | 1.3M | 15.9K |
EPS (Basic) | ₹-0.01 | ₹0.00 | ₹-0.02 | ₹0.00 | ₹0.00 |
EPS (Diluted) | ₹-0.01 | ₹0.00 | ₹-0.02 | ₹0.00 | ₹0.00 |
Basic Shares Outstanding | 583800000 | 550000000 | 550000000 | 550000000 | 55000000 |
Diluted Shares Outstanding | 583800000 | 550000000 | 550000000 | 550000000 | 55000000 |
Income Statement Trend
Johnson Pharmacare Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 77.0K | 14.0K | 18.0K | 406.0K | 2.3M |
Short-term Investments | 67.0K | 1.0K | 2.0K | 23.0K | 1.0K |
Accounts Receivable | 0 | 0 | 0 | 10.5M | 16.8M |
Inventory | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13.5M | - | 16.0K | - | - |
Total Current Assets | 156.3M | 14.0K | 18.0K | 10.9M | 56.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | 1.0K | 1.0K | 1.0K | - |
Total Non-Current Assets | 422.9M | 598.3M | 598.3M | 588.9M | 538.8M |
Total Assets | 579.3M | 598.3M | 598.3M | 599.8M | 594.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 0 | 0 | 0 | 0 | 6.5M |
Short-term Debt | 0 | 0 | 0 | 0 | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 11.5M | 11.3M | 9.8M | 388.7K | 4.1K |
Total Current Liabilities | 11.5M | 11.3M | 9.8M | 11.3M | 6.5M |
Non-Current Liabilities | |||||
Long-term Debt | 6.1M | 19.5M | 19.1M | 6.1M | 6.9M |
Deferred Tax Liabilities | - | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.0K | - | - | - | - |
Total Non-Current Liabilities | 6.1M | 19.5M | 19.1M | 6.1M | 6.9M |
Total Liabilities | 17.6M | 30.8M | 28.8M | 17.4M | 13.4M |
Equity | |||||
Common Stock | 550.0M | 550.0M | 550.0M | 550.0M | 500.0M |
Retained Earnings | - | -26.5M | -24.5M | -11.6M | -12.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 561.7M | 567.5M | 569.5M | 582.4M | 581.4M |
Key Metrics | |||||
Total Debt | 6.1M | 19.5M | 19.1M | 6.1M | 6.9M |
Working Capital | 144.8M | -11.2M | -9.7M | -440.0K | 49.5M |
Balance Sheet Composition
Johnson Pharmacare Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -5.8M | -2.0M | -13.3M | 1.3M | 11.7K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -13.3M | 1.5M | 8.9M | 54.5M | -7.6M |
Operating Cash Flow | -19.1M | -454.0K | -4.4M | 55.8M | -7.6M |
Investing Activities | |||||
Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
Acquisitions | 32.7M | 0 | 86.2M | 0 | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | 32.7M | 0 | 86.2M | 0 | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 0 | 450.0K | 13.0M | -830.0K | 622.4K |
Free Cash Flow | -19.1M | -454.0K | -4.0M | 49.0M | -1.1M |
Net Change in Cash | 13.6M | -4.0K | 94.8M | 55.0M | -7.0M |
Cash Flow Trend
Johnson Pharmacare Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-79.00
Price to Book
0.72
Price to Sales
-130.32
PEG Ratio
0.79
Profitability Ratios
Profit Margin
0.00%
Operating Margin
127.68%
Return on Equity
-1.04%
Return on Assets
-1.01%
Financial Health
Current Ratio
13.58
Debt to Equity
1.08
Beta
-0.90
Per Share Data
EPS (TTM)
₹-0.01
Book Value per Share
₹1.09
Revenue per Share
₹-0.01
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
johnpharma | 434.5M | -79.00 | 0.72 | -1.04% | 0.00% | 1.08 |
Beml Land Assets | 8.7B | -231.69 | 785.55 | -337.59% | 0.00% | 779.28 |
Cupid Breweries | 5.1B | 131.04 | - | 29.53% | -119.62% | -4.02 |
Yash Trading | 1.7B | - | 7.52 | -15.07% | 8.83% | 0.00 |
Vr Woodart | 762.6M | -580.33 | -36.93 | 6.17% | 0.00% | -1.00 |
Transchem | 571.5M | 12.55 | 0.72 | 6.59% | 53.20% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.